Development of RNA interference as a novel class of therapeutics requires improved
pharmacokinetic properties of short interfering RNA (siRNA). To confer enhanced serum …

In the 10 years that have passed since the Nobel prize-winning discovery of RNA
interference (RNAi), billions of dollars have been invested in the therapeutic application of …

RNA interference (RNAi) as a mechanism to selectively degrade mRNA (mRNA) expression
has emerged as a potential novel approach for drug target validation and the study of …

In 1998, the RNA interference discovery by Fire and Mello revolutionized the scientific and
therapeutic world. They showed that small double-stranded RNAs, the siRNAs, were …

The approval of the first small interfering RNA (siRNA) drug Patisiran by FDA in 2018 marks
a new era of RNA interference (RNAi) therapeutics. MicroRNAs (miRNA), an important post …

ABSTRACT RNA interference has emerged as a potentially powerful tool in the treatment of
genetic and acquired diseases by delivering short interfering RNA (siRNA) or microRNA …

To use siRNA (small interfering ribonucleic acids) for systemic administration, a delivery
system is often necessary to overcome barriers between administration and the target sites …

Application of siRNA to knockdown a specific gene requires target mRNA accessibility,
effective intracellular delivery of siRNA into target cells and potent siRNA inhibition of target …

RNA interference (RNAi) quietly crept into biological research in the 1990s when
unexpected gene-silencing phenomena in plants and flatworms first perplexed scientists …

RNA interference is an evolutionarily conserved gene-silencing phenomenon that shows
great promise for developing new therapies. However, the development of small interfering …